Analyst Activity – Morgan Stanley Lowers Its Price Target On Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) to $38.00

Analyst Ratings For Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)

Story continues below

Today, Morgan Stanley lowered its price target on Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) to $38.00 per share.

There are 5 buy ratings on the stock.

The current consensus rating on Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN) is Buy (Score: 3.00) with a consensus target price of $40.80 per share, a potential 23.34% upside.

Some recent analyst ratings include

  • 9/12/2017-Piper Jaffray Companies Reiterated Rating of Buy.
  • 5/30/2017-William Blair initiated coverage with a Outperform rating.
  • 5/30/2017-Barclays PLC initiated coverage with a Overweight rating.


    Recent Trading Activity for Biohaven Pharmaceutical Holding Co Ltd (NASDAQ:BHVN)
    Shares of Biohaven Pharmaceutical Holding Co Ltd closed the previous trading session at with shares trading hands.

    An ad to help with our costs